FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2120210375> ?p ?o ?g. }

• W2120210375 endingPage "e41410" @default.
• W2120210375 startingPage "e41410" @default.
• W2120210375 abstract "Background Epidermal growth factor receptor (EGFR) is overexpressed in many solid tumor types, such as ovarian carcinoma. Immunoliposome based drug targeting has shown promising results in drug delivery to the tumors. However, the ratio of tumor-to-normal tissue concentrations should be increased to minimize the adverse effects of cytostatic drugs. Methodology/Principal Findings We studied the EGFR-targeted doxorubicin immunoliposomes using pre-targeting and local intraperitoneal (i.p.) administration of the liposomes. This approach was used to increase drug delivery to tumors as compared to direct intravenous (i.v.) administration of liposomes. EGFR antibodies were attached on the surface of PEG coated liposomes using biotin-neutravidin binding. Receptor mediated cellular uptake and cytotoxic efficacy of EGFR-targeted liposomes were investigated in human ovarian adenocarcinoma (SKOV-3 and SKOV3.ip1) cells. In vivo distribution of the liposomes in mice was explored using direct and pre-targeting approaches and SPECT/CT imaging. Targeted liposomes showed efficient and specific receptor-mediated binding to ovarian carcinoma cells in vitro, but the difference in cytotoxicity between targeted and non-targeted liposomes remained small. The relatively low cytotoxic efficacy is probably due to insufficient doxorubicin release from the liposomes rather than lack of target binding. Tumor uptake of targeted liposomes in vivo was comparable to that of non-targeted liposomes after both direct and pre-targeting administration. For both EGFR-targeted and non-targeted liposomes, the i.p. administration increased liposome accumulation to the tumors compared to i.v. injections. Conclusions/Significance Intraperitoneal administration of liposomes may be a beneficial approach to treat the tumors in the abdominal cavity. The i.p. pre-targeting method warrants further studies as a potential approach in cancer therapy." @default.
• W2120210375 created "2016-06-24" @default.
• W2120210375 creator A5000931343 @default.
• W2120210375 creator A5004892675 @default.
• W2120210375 creator A5006378832 @default.
• W2120210375 creator A5022065670 @default.
• W2120210375 creator A5027118212 @default.
• W2120210375 creator A5029738142 @default.
• W2120210375 creator A5030135160 @default.
• W2120210375 creator A5050892084 @default.
• W2120210375 creator A5053032683 @default.
• W2120210375 creator A5056343360 @default.
• W2120210375 creator A5063101221 @default.
• W2120210375 creator A5065810893 @default.
• W2120210375 creator A5070938637 @default.
• W2120210375 creator A5080754209 @default.
• W2120210375 date "2012-07-26" @default.
• W2120210375 modified "2023-10-18" @default.
• W2120210375 title "Pre-Targeting and Direct Immunotargeting of Liposomal Drug Carriers to Ovarian Carcinoma" @default.
• W2120210375 cites W1972645118 @default.
• W2120210375 cites W1977258258 @default.
• W2120210375 cites W1979162895 @default.
• W2120210375 cites W1993342139 @default.
• W2120210375 cites W1995302565 @default.
• W2120210375 cites W2002975415 @default.
• W2120210375 cites W2003923108 @default.
• W2120210375 cites W2004224153 @default.
• W2120210375 cites W2004305723 @default.
• W2120210375 cites W2005293308 @default.
• W2120210375 cites W2021118385 @default.
• W2120210375 cites W2022288450 @default.
• W2120210375 cites W2026316991 @default.
• W2120210375 cites W2032001097 @default.
• W2120210375 cites W2039350685 @default.
• W2120210375 cites W2048834254 @default.
• W2120210375 cites W2051654117 @default.
• W2120210375 cites W2051777299 @default.
• W2120210375 cites W2056644518 @default.
• W2120210375 cites W2058114341 @default.
• W2120210375 cites W2066263765 @default.
• W2120210375 cites W2066986283 @default.
• W2120210375 cites W2068861538 @default.
• W2120210375 cites W2078816993 @default.
• W2120210375 cites W2082211942 @default.
• W2120210375 cites W2091239986 @default.
• W2120210375 cites W2095142763 @default.
• W2120210375 cites W2105783608 @default.
• W2120210375 cites W2117584556 @default.
• W2120210375 cites W2124458286 @default.
• W2120210375 cites W2125210489 @default.
• W2120210375 cites W2129404315 @default.
• W2120210375 cites W2131748204 @default.
• W2120210375 cites W2156969927 @default.
• W2120210375 cites W2159995951 @default.
• W2120210375 cites W4244120980 @default.
• W2120210375 doi "https://doi.org/10.1371/journal.pone.0041410" @default.
• W2120210375 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3406029" @default.
• W2120210375 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22844475" @default.
• W2120210375 hasPublicationYear "2012" @default.
• W2120210375 type Work @default.
• W2120210375 sameAs 2120210375 @default.
• W2120210375 citedByCount "51" @default.
• W2120210375 countsByYear W21202103752012 @default.
• W2120210375 countsByYear W21202103752013 @default.
• W2120210375 countsByYear W21202103752014 @default.
• W2120210375 countsByYear W21202103752015 @default.
• W2120210375 countsByYear W21202103752016 @default.
• W2120210375 countsByYear W21202103752017 @default.
• W2120210375 countsByYear W21202103752018 @default.
• W2120210375 countsByYear W21202103752019 @default.
• W2120210375 countsByYear W21202103752020 @default.
• W2120210375 countsByYear W21202103752021 @default.
• W2120210375 countsByYear W21202103752022 @default.
• W2120210375 countsByYear W21202103752023 @default.
• W2120210375 crossrefType "journal-article" @default.
• W2120210375 hasAuthorship W2120210375A5000931343 @default.
• W2120210375 hasAuthorship W2120210375A5004892675 @default.
• W2120210375 hasAuthorship W2120210375A5006378832 @default.
• W2120210375 hasAuthorship W2120210375A5022065670 @default.
• W2120210375 hasAuthorship W2120210375A5027118212 @default.
• W2120210375 hasAuthorship W2120210375A5029738142 @default.
• W2120210375 hasAuthorship W2120210375A5030135160 @default.
• W2120210375 hasAuthorship W2120210375A5050892084 @default.
• W2120210375 hasAuthorship W2120210375A5053032683 @default.
• W2120210375 hasAuthorship W2120210375A5056343360 @default.
• W2120210375 hasAuthorship W2120210375A5063101221 @default.
• W2120210375 hasAuthorship W2120210375A5065810893 @default.
• W2120210375 hasAuthorship W2120210375A5070938637 @default.
• W2120210375 hasAuthorship W2120210375A5080754209 @default.
• W2120210375 hasBestOaLocation W21202103751 @default.
• W2120210375 hasConcept C109316439 @default.
• W2120210375 hasConcept C112705442 @default.
• W2120210375 hasConcept C121608353 @default.
• W2120210375 hasConcept C126322002 @default.
• W2120210375 hasConcept C126511603 @default.
• W2120210375 hasConcept C13245373 @default.
• W2120210375 hasConcept C150903083 @default.
• W2120210375 hasConcept C178790620 @default.

• next